Indication

Prevention of Mycobacterium avium complex disease

The prevention of *Mycobacterium avium* complex disease is a prophylactic clinical strategy targeted primarily at severely immunocompromised individuals, most notably patients with advanced human immunodeficiency virus infection presenting with CD4 T-lymphocyte counts below 50 cells/µL. Read more about Prevention of Mycobacterium avium complex disease

32 drugs 30 manufacturers

Advertisement

Drugs that treat it

Common Prevention of Mycobacterium avium complex disease therapies.

Showing 10–18 of 32 drugs

CLARITHROMYCIN

MACROLIDE ANTIBIOTICS·DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX INFECTION·+28
Lannett Company

CLARITHROMYCIN

DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX INFECTION·+28
ROXANE/WEST-WAR

CLARITHROMYCIN

DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX INFECTION·+28
CADISTA PHARMAC

CLARITHROMYCIN

MACROLIDE ANTIBIOTICS·DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX INFECTION·+28
RISING PHARM

CLARITHROMYCIN

MACROLIDE ANTIBIOTICS·DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX INFECTION·+28
Major Pharamceuticals

CLARITHROMYCIN

MACROLIDE ANTIBIOTICS·DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX INFECTION·+28
STRIDES PHARMA

RIFABUTIN

RIFAMYCINS·PREVENTION OF MYCOBACTERIUM AVIUM COMPLEX DISEASE
GSK Consumer Healthcare

CLARITHROMYCIN

MACROLIDE ANTIBIOTICS·DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX INFECTION·+28
QUALITY CARE
Filter & compare in the drug finder →Opens the drug finder with Prevention of Mycobacterium avium complex disease preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Prevention of Mycobacterium avium complex disease.

The prevention of *Mycobacterium avium* complex disease is a prophylactic clinical strategy targeted primarily at severely immunocompromised individuals, most notably patients with advanced human immunodeficiency virus infection presenting with CD4 T-lymphocyte counts below 50 cells/µL.

*Mycobacterium avium* complex comprises environmental nontuberculous mycobacteria—principally *M.

avium* and *M.

intracellulare*—that can colonize the respiratory or gastrointestinal tracts.

In profound immunosuppression, impaired cell-mediated immunity permits hematogenous dissemination of the bacilli across multiple organ systems, resulting in severe systemic manifestations such as debilitating fevers, night sweats, profound weight loss, severe anemia, hepatosplenomegaly, and bacteremia.

Prophylactic therapy aims to forestall this life-threatening disseminated bacteremic infection before it becomes established.

Personalize your experience

Follow Prevention of Mycobacterium avium complex disease and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it